Mustang Bio Inc (MBIO)
NASDAQ:MBIO
Want to see MBIO full AI Analyst Report?
MBIO Stock Chart & Stats
$1.09
-$0.01(-4.59%)
At close: 4:00 PM EST
$1.09
-$0.01(-4.59%)
Day’s Range― - ―
52-Week Range$0.53 - $7.00
Previous CloseN/A
Volume2.68M
Average Volume (3M)94.14K
Market Cap
$5.51M
Enterprise Value-$10.98M
Total Cash (Recent Filing)$17.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,732,120
10 Day Avg. Volume88,215
30 Day Avg. Volume94,141
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-9.15
Enterprise Value/Market Cap-1.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit267.90
Enterprise Value/Ebitda5.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnThe material reduction in cash burn over multiple years shows meaningful cost discipline and operational tightening. That steady improvement reduces near-term financing pressure, lengthens runway, and increases the odds that current programs can advance across key clinical inflection points without immediate dilutive financings.
Low Leverage / No DebtHaving no reported debt provides structural financial flexibility: lower fixed obligations, simpler capital structure, and better ability to negotiate future financing or partnerships. For a pre-commercial biotech, minimal leverage reduces bankruptcy risk and preserves optionality to fund trials or strike deals.
Strategic Focus On Gene & Cell TherapiesA pipeline concentrated on engineered cell and gene therapies aligns with durable industry secular tailwinds, high barriers to entry, and attractive long-term pricing and demand dynamics for curative or specialty indications. This strategic positioning supports significant upside if clinical progress translates to approvals or partnerships.
Bears Say
No RevenueAbsence of any product revenue makes the business wholly dependent on financing and partnerships for operating continuity. Without commercial sales, there's limited evidence of sustainable cash generation or scalable margins, leaving long-term viability contingent on successful clinical outcomes or external transactions.
Persistent Negative Free Cash FlowEven with improving burn, free cash flow remains negative, meaning the company must access capital markets or partners to fund development. Repeated financing needs typically dilute existing shareholders, can shift strategic priorities, and create execution risk if fundraising windows close or terms worsen.
Historic Equity Volatility & Shrinking Asset BasePast periods of negative equity and materially reduced assets point to historical financial stress and restructuring. That history reduces the company's financial cushion, complicates partner negotiations, and signals a higher probability of future dilutive financings or asset-sales to sustain operations if clinical timelines slip.
Mustang Bio News
MBIO FAQ
What was Mustang Bio Inc’s price range in the past 12 months?
Mustang Bio Inc lowest stock price was $0.53 and its highest was $7.00 in the past 12 months.
What is Mustang Bio Inc’s market cap?
Mustang Bio Inc’s market cap is $5.51M.
When is Mustang Bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mustang Bio Inc’s earnings last quarter?
Currently, no data Available
Is Mustang Bio Inc overvalued?
According to Wall Street analysts Mustang Bio Inc’s price is currently Overvalued.
Does Mustang Bio Inc pay dividends?
Mustang Bio Inc does not currently pay dividends.
What is Mustang Bio Inc’s EPS estimate?
Mustang Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mustang Bio Inc have?
Mustang Bio Inc has 6,732,120 shares outstanding.
What happened to Mustang Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mustang Bio Inc?
Currently, no hedge funds are holding shares in MBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Silexion Therapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
8.01% Insiders
1.11% Mutual Funds
<0.01% Other Institutional Investors
90.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---